Systemic Sclerosis Center of Research Translation


Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis.
Fleury M, Belkina AC, Proctor EA, Zammitti C, Simms RW, Lauffenburger DA, Snyder-Cappione JE, Lafyatis R, Dooms H.
Arthritis Rheumatol. 2017 Dec 15. doi: 10.1002/art.40399. [Epub ahead of print]

SFRP2/DPP4 and FMO1/LSP1 Define Major Fibroblast Populations in Human Skin.
Tabib T, Morse C, Wang T, Chen W, Lafyatis R.
J Invest Dermatol. 2017 Dec 6. pii: S0022-202X(17)33069-5. doi: 10.1016/j.jid.2017.09.045. [Epub ahead of print]

Inhibition of β-Catenin Signaling in the Skin Rescues Cutaneous Adipogenesis in Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial of C-82.
Lafyatis R, Mantero JC, Gordon J, Kishore N, Carns M, Dittrich H, Spiera R, Simms RW, Varga J.
J Invest Dermatol. 2017 Dec;137(12):2473-2483. doi: 10.1016/j.jid.2017.06.032. Epub 2017 Aug 12.

14-3-3z sequesters cytosolic T-bet, upregulating IL-13 levels in TC2 and CD8+ lymphocytes from patients with scleroderma.
Cascio S, Medsger TA Jr, Hawse WF, Watkins SC, Milcarek C, Moreland LW, Lafyatis RA, Fuschiotti P.
J Allergy Clin Immunol. 2017 Nov 15. pii: S0091-6749(17)31760-8. doi: 10.1016/j.jaci.2017.10.029. [Epub ahead of print]

Development and validation of a patient-reported outcome instrument for skin involvement in patients with systemic sclerosis.
Man A, Correa JK, Ziemek J, Simms RW, Felson DT, Lafyatis R.
Ann Rheum Dis. 2017 Aug;76(8):1374-1380. doi: 10.1136/annrheumdis-2016-210534. Epub 2017 Feb 17.

Blockade of PDGF Receptors by Crenolanib Has Therapeutic Effect in Patient Fibroblasts and in Preclinical Models of Systemic Sclerosis.
Makino K, Makino T, Stawski L, Mantero JC, Lafyatis R, Simms R, Trojanowska M.
J Invest Dermatol. 2017 Aug;137(8):1671-1681. doi: 10.1016/j.jid.2017.03.032. Epub 2017 Apr 19.

Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature.
Derrett-Smith EC, Martyanov V, Chighizola CB, Moinzadeh P, Campochiaro C, Khan K, Wood TA, Meroni PL, Abraham DJ, Ong VH, Lafyatis R, Whitfield ML, Denton CP.
Arthritis Res Ther. 2017 Jul 4;19(1):156. doi: 10.1186/s13075-017-1360-7.
Increased dermal collagen bundle alignment in systemic sclerosis is associated with a cell migration signature and role of Arhgdib in directed fibroblast migration on aligned ECMs.
Cao L, Lafyatis R, Burkly LC.
PLoS One. 2017 Jun 29;12(6):e0180751. doi: 10.1371/journal.pone.0180751. eCollection 2017.

Skin-Resident Effector Memory CD8+CD28- T Cells Exhibit a Profibrotic Phenotype in Patients with Systemic Sclerosis.
Li G, Larregina AT, Domsic RT, Stolz DB, Medsger TA Jr, Lafyatis R, Fuschiotti P.
J Invest Dermatol. 2017 May;137(5):1042-1050. doi: 10.1016/j.jid.2016.11.037. Epub 2016 Dec 22.

A Proteome-Derived Longitudinal Pharmacodynamic Biomarker for Diffuse Systemic Sclerosis Skin.
Rice LM, Mantero JC, Stifano G, Ziemek J, Simms RW, Gordon J, Domsic R, Lafyatis R.
J Invest Dermatol. 2017 Jan;137(1):62-70. doi: 10.1016/j.jid.2016.08.027. Epub 2016 Sep 14.

Editorial: Epigenetics in Systemic Sclerosis.
Lafyatis R.
Arthritis Rheumatol. 2016 Dec;68(12):2841-2844. doi: 10.1002/art.39830. No abstract available.

Altered Dermal Fibroblasts in Systemic Sclerosis Display Podoplanin and CD90.
Nazari B, Rice LM, Stifano G, Barron AM, Wang YM, Korndorf T, Lee J, Bhawan J, Lafyatis R, Browning JL.
Am J Pathol. 2016 Oct;186(10):2650-64. doi: 10.1016/j.ajpath.2016.06.020. Epub 2016 Aug 23.

miR-155 in the progression of lung fibrosis in systemic sclerosis.
Christmann RB, Wooten A, Sampaio-Barros P, Borges CL, Carvalho CR, Kairalla RA, Feghali-Bostwick C, Ziemek J, Mei Y, Goummih S, Tan J, Alvarez D, Kass DJ, Rojas M, de Mattos TL, Parra E, Stifano G, Capelozzi VL, Simms RW, Lafyatis R.
Arthritis Res Ther. 2016 Jul 5;18(1):155. doi: 10.1186/s13075-016-1054-6.

The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis.
Ziemek J, Man A, Hinchcliff M, Varga J, Simms RW, Lafyatis R.
Rheumatology (Oxford). 2016 May;55(5):911-7. doi: 10.1093/rheumatology/kew003. Epub 2016 Feb 15.

The HLA-B 35 allele modulates ER stress, inflammation and proliferation in PBMCs from Limited Cutaneous Systemic Sclerosis patients.
Lenna S, Assassi S, Farina GA, Mantero JC, Scorza R, Lafyatis R, Farber HW, Trojanowska M.
Arthritis Res Ther. 2015 Dec 16;17:363. doi: 10.1186/s13075-015-0881-1.

Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients.
Rice LM, Padilla CM, McLaughlin SR, Mathes A, Ziemek J, Goummih S, Nakerakanti S, York M, Farina G, Whitfield ML, Spiera RF, Christmann RB, Gordon JK, Weinberg J, Simms RW, Lafyatis R.
J Clin Invest. 2015 Jul 1;125(7):2795-807. doi: 10.1172/JCI77958. Epub 2015 Jun 22.

CpGB DNA activates dermal macrophages and specifically recruits inflammatory monocytes into the skin.
Mathes AL, Rice L, Affandi AJ, DiMarzio M, Rifkin IR, Stifano G, Christmann RB, Lafyatis R.
Exp Dermatol. 2015 Feb;24(2):133-9. doi: 10.1111/exd.12603. Epub 2015 Jan 12.

Transforming growth factor β–at the centre of systemic sclerosis.
Lafyatis R.
Nat Rev Rheumatol. 2014 Dec;10(12):706-19. doi: 10.1038/nrrheum.2014.137. Epub 2014 Aug 19. Review.


Contact Us

Division of Rheumatology and Clinical Immunology Offices

S700 Biomedical Science Tower
3500 Terrace Street
Pittsburgh, PA 15261
412-383-8000  |  Email Us

For Patients